Sagimet Biosciences (SGMT) Common Equity (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Common Equity of $102.5 million for Q1 2026, down 26.28% year-over-year from $139.0 million in Q1 2025, and down 8.01% quarter-over-quarter from $111.4 million in Q4 2025.
Sagimet Biosciences (SGMT) Common Equity (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Common Equity history runs 5 years deep, the most recent figure standing at $102.5 million for Q1 2026.
- In Q1 2026, Common Equity fell 26.28% year-over-year to $102.5 million; the TTM figure through Mar 2026 stood at $102.5 million (down 26.28% YoY), while the FY2025 annual figure was $111.4 million, down 28.51% from the prior year.
- Common Equity for Q1 2026 stood at $102.5 million, down from $111.4 million in the prior quarter.
- The five-year high for Common Equity was $190.0 million in Q1 2024, with the low at -$198.4 million in Q2 2023.
- The 5-year median for Common Equity is $106.9 million (2025), against an average of $34.9 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity surged 198.61% in 2024, then slumped 30.13% in 2025.
- Sagimet Biosciences' Common Equity stood at -$187.0 million in 2022, then jumped by 148.71% to $91.1 million in 2023, then surged by 71.09% to $155.8 million in 2024, then fell by 28.51% to $111.4 million in 2025, then fell by 8.01% to $102.5 million in 2026.
- Business Quant data shows SGMT's Common Equity at $102.5 million in Q1 2026, $111.4 million in Q4 2025, and $119.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | 256.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256.16 Mn |
| Mar 31, 2026 | 102.46 Mn |
| Dec 31, 2025 | 111.38 Mn |
| Sep 30, 2025 | 119.26 Mn |
| Jun 30, 2025 | 130.16 Mn |
| Mar 31, 2025 | 138.99 Mn |
| Dec 31, 2024 | 155.81 Mn |
| Sep 30, 2024 | 170.68 Mn |
| Jun 30, 2024 | 183.29 Mn |
| Mar 31, 2024 | 190.02 Mn |
| Dec 31, 2023 | 91.07 Mn |
| Sep 30, 2023 | 97.88 Mn |
| Jun 30, 2023 | -198.41 Mn |
| Mar 31, 2023 | -192.70 Mn |
| Dec 31, 2022 | -186.95 Mn |
| Sep 30, 2022 | -180.55 Mn |
| Jun 30, 2022 | -173.42 Mn |